rolistobart   Click here for help

GtoPdb Ligand ID: 14652

Compound class: Antibody
Comment: Rolistobart is an anti-leukocyte immunoglobulin like receptor B4 (LILRB4) monoclonal antibody. It is proposed as an immunotherapeutic that is designed to disrupt the immunosuppressive LILRB4 checkpoint, and to restore anti-tumour immunity. Peptide sequences for the heavy and light chains of the antibody are claimed in Merck patent US11111297B2, with the humanized antibody referred to as mAb 46 (52B8 VH1 M64V/VL5 N34Q IgG4 S228P/Kappa) [1]. Rolistobart is likely intended as the INN for MK-0482.
Click here for help
No information available.
Summary of Clinical Use Click here for help
MK-0482 was progressed as an immuno-oncology agent.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04165070 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) Phase 1/Phase 2 Interventional Merck Sharp & Dohme LLC
NCT04165083 KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) Phase 2 Interventional Merck Sharp & Dohme LLC
NCT06413095 PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS Early Phase 1 Interventional Presage Biosciences